BALAXI PHARMACEUTICALS LIMITED — PPTs, 08-08-2025: Investor Presentation

Here's a summary of the attached file:

**Financial Highlights:**

Q1 FY26 revenue grew 8% YoY to ₹70.74 Cr, maintaining a 44% gross margin. Profit After Tax sharply declined to ₹3.29 Cr (vs ₹6.48 Cr in Q1 FY25), attributed to higher operational costs including one-time write-offs and the Nicaragua business not yet at break-even. EPS was ₹0.62.

**Strategic Initiatives & Growth Drivers:**

Balaxi's first pharma formulation facility in Hyderabad is nearing completion, with stability batch production expected early September. This "Asset Right" shift targets backward integration, margin enhancement, and new market access. They secured 14 new product registrations in Q1, totaling 929, with plans for geographic expansion into Ecuador, Chile, and other emerging markets.

**Business Developments:**

The company holds 929 product registrations across seven countries (300+ in pipeline). Digital tools support procurement and regulatory management.

**Market Position & Competitive Advantage:**

Balaxi is an IPR-driven pharma leader in Latin American and African frontier markets. Its competitive edge is a focus on low-competition regions, leveraging local teams, and robust in-house regulatory systems.

**Investor Implications:**

Strategic manufacturing investment and consistent product registrations signal positive growth potential. However, the Q1 PAT decline from operational costs and new market integration presents execution risks to monitor.